Navigation Links
Smith & Nephew Orthopaedics Donates Inaugural Funds to COTA Grants Program
Date:10/29/2009

MEMPHIS, Tenn., Oct. 29 /PRNewswire-FirstCall/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Orthopaedics business announced today it has made a first-of-its-kind contribution to the Center for Orthopaedic Trauma Advancement (COTA) for fellowship and resident education grants.

Smith & Nephew and COTA entered into a grant administration agreement in September under which COTA will serve as an independent, third-party administrator of funds. Smith & Nephew is providing COTA's first donation to support research, fellowship and residency programs for orthopaedic surgeons serving the multiply-injured patient.

COTA is the first 501 (c) (3) non-profit corporation exclusively dedicated to funding medical education for surgeons who specialize in orthopaedic trauma patient care. The organization is working to build on Smith & Nephew's contribution with additional grants from industry, as well as non-profit entities and philanthropic sources.

"We are proud to donate the first funds to COTA as they create an important avenue for the independent selection and distribution of grants," said Bill Shopoff, president of Smith & Nephew Orthopaedics' Trauma business. "This agreement reinforces our commitment to training and education for the physicians who deliver life-restoring trauma technology to patients."

About Smith & Nephew

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew


'/>"/>
SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Applauds Compassion, Competence, Passion and Perseverance in North Carolinas Child Advocates
2. Members to Benefit from New Agreement between Amerinet and B. E. Smith
3. Deane Smith Media Innovations Selected By Tennessee Medical Association For Marketing, PR
4. Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting
5. Mens Health Network, The Washington Redskins and GlaxoSmithKline Team Up for Septembers Prostate Cancer Awareness Month
6. The Celebrate Wellness Expo Presents Motivational Speaker & Author Dr. Robin L. Smith and Spiritual Teacher & Author Rev. Michael Bernard Beckwith
7. By 2018, GlaxoSmithKlines Votrient Will Garner Sales of $640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader
8. Dr. Smith Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept. 10
9. Dr. Smith Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept 10
10. European Launch of Acticoat(TM) Flex with NUCRYSTs Nanocrystalline Silver Technology Announced by Smith Nephew
11. Mission Pharmacal Acquires Dr. Smiths Diaper Ointment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology: